A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931

@inproceedings{Ozkaynak2018ACS,
  title={A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931},
  author={Mehmet Fevzi Ozkaynak and Andrew L Gilman and Wendy B London and Arlene H Naranjo and Mitchell B. Diccianni and Sheena C. Tenney and Malcolm Smith and Karen S Messer and Robert C. Seeger and C Patrick Reynolds and L. Mary Smith and Barry L. Shulkin and Marguerite T. Parisi and John M. Maris and Julie Park and Paul M. Sondel and Alice Yu},
  booktitle={Front. Immunol.},
  year={2018}
}
Purpose A phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was designed to collect FDA-required safety/toxicity data to support FDA registration of ch14.18. Experimental… CONTINUE READING